Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
TARO's Cash-to-Debt is ranked higher than
98% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. TARO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TARO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.23 Max: No Debt
Current: No Debt
Equity-to-Asset 0.90
TARO's Equity-to-Asset is ranked higher than
90% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TARO: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
TARO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.47 Max: 0.9
Current: 0.9
0.12
0.9
Interest Coverage 50.58
TARO's Interest Coverage is ranked lower than
55% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. TARO: 50.58 )
Ranked among companies with meaningful Interest Coverage only.
TARO' s Interest Coverage Range Over the Past 10 Years
Min: 2.59  Med: 207.4 Max: No Debt
Current: 50.58
Piotroski F-Score: 5
Altman Z-Score: 13.64
Beneish M-Score: -2.65
WACC vs ROIC
4.21%
28.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 58.56
TARO's Operating Margin % is ranked higher than
99% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. TARO: 58.56 )
Ranked among companies with meaningful Operating Margin % only.
TARO' s Operating Margin % Range Over the Past 10 Years
Min: 13.31  Med: 44.73 Max: 64.63
Current: 58.56
13.31
64.63
Net Margin % 51.89
TARO's Net Margin % is ranked higher than
98% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. TARO: 51.89 )
Ranked among companies with meaningful Net Margin % only.
TARO' s Net Margin % Range Over the Past 10 Years
Min: 9.28  Med: 37.91 Max: 56.9
Current: 51.89
9.28
56.9
ROE % 23.23
TARO's ROE % is ranked higher than
89% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. TARO: 23.23 )
Ranked among companies with meaningful ROE % only.
TARO' s ROE % Range Over the Past 10 Years
Min: 19.01  Med: 35.23 Max: 49.88
Current: 23.23
19.01
49.88
ROA % 20.66
TARO's ROA % is ranked higher than
94% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. TARO: 20.66 )
Ranked among companies with meaningful ROA % only.
TARO' s ROA % Range Over the Past 10 Years
Min: 6.38  Med: 24.38 Max: 32.05
Current: 20.66
6.38
32.05
ROC (Joel Greenblatt) % 42.50
TARO's ROC (Joel Greenblatt) % is ranked higher than
85% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. TARO: 42.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TARO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.67  Med: 50.57 Max: 105.96
Current: 42.5
17.67
105.96
3-Year Revenue Growth Rate 7.50
TARO's 3-Year Revenue Growth Rate is ranked higher than
74% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. TARO: 7.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TARO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.8  Med: 13.1 Max: 34.7
Current: 7.5
-6.8
34.7
3-Year EBITDA Growth Rate 7.10
TARO's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. TARO: 7.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TARO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.5  Med: 27.8 Max: 63.7
Current: 7.1
-24.5
63.7
3-Year EPS without NRI Growth Rate 10.70
TARO's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. TARO: 10.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TARO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 38.4 Max: 119
Current: 10.7
0
119
GuruFocus has detected 2 Warning Signs with Taro Pharmaceutical Industries Ltd $TARO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TARO's 30-Y Financials

Financials (Next Earnings Date: 2017-08-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

TARO Guru Trades in Q2 2016

Paul Tudor Jones 2,663 sh (New)
David Dreman 257 sh (+49.42%)
Jim Simons 620,900 sh (+26.38%)
HOTCHKIS & WILEY 151,330 sh (+1.58%)
» More
Q3 2016

TARO Guru Trades in Q3 2016

Paul Tudor Jones 7,636 sh (+186.74%)
David Dreman 414 sh (+61.09%)
Jim Simons 629,900 sh (+1.45%)
HOTCHKIS & WILEY Sold Out
» More
Q4 2016

TARO Guru Trades in Q4 2016

Paul Tudor Jones 14,160 sh (+85.44%)
Jim Simons 547,600 sh (-13.07%)
David Dreman 36 sh (-91.30%)
» More
Q1 2017

TARO Guru Trades in Q1 2017

Paul Tudor Jones 14,789 sh (+4.44%)
David Dreman Sold Out
Jim Simons 306,200 sh (-44.08%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:NYSE:MNK, NAS:AKRX, NYSE:VRX, NYSE:CTLT, OTCPK:STDAF, NAS:OPK, NYSE:PTHN, NAS:ENDP, NAS:MDCO, NAS:IRWD, OTCPK:HYPMY, NYSE:RDY, OTCPK:GZPHY, OTCPK:EVTCY, NAS:PCRX, NAS:SUPN, NAS:HZNP, NAS:RDUS, NAS:PAHC, NYSE:DPLO » details
Traded in other countries:TAL.Germany,
Headquarter Location:Israel
Taro Pharmaceutical Industries Ltd is a multinational, science-based pharmaceutical company. It develops manufactures and markets Rx and OTC pharmaceutical products in the United States, Canada and Israel.

Israeli company Taro Pharmaceutical Industries sells generic drugs primarily in the U.S. It produces a significant portion of its own active drug ingredients. Taro in-licensed several branded products from Medicis, which it promotes to U.S. dermatologists and pediatricians through a 60-person salesforce. The firm's experimental treatment for essential tremor, T2000, is approved for a Phase III study in Canada but has yet to receive approval to enter Phase III in the U.S.

Top Ranked Articles about Taro Pharmaceutical Industries Ltd

Gurus' Stocks With Low P/E Ratios Some of the stocks have wide margins of safety
Gurus are buying stocks that are trading with low price-earnings (P/E) ratios. Some are greatly undervalued, according to the DCF calculator. Read more...

Ratios

vs
industry
vs
history
PE Ratio 9.39
TARO's PE Ratio is ranked higher than
91% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. TARO: 9.39 )
Ranked among companies with meaningful PE Ratio only.
TARO' s PE Ratio Range Over the Past 10 Years
Min: 3.13  Med: 10.17 Max: 20.41
Current: 9.39
3.13
20.41
PE Ratio without NRI 9.39
TARO's PE Ratio without NRI is ranked higher than
91% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. TARO: 9.39 )
Ranked among companies with meaningful PE Ratio without NRI only.
TARO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.84  Med: 10.16 Max: 20.41
Current: 9.39
2.84
20.41
Price-to-Owner-Earnings 9.50
TARO's Price-to-Owner-Earnings is ranked higher than
89% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. TARO: 9.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TARO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.5  Med: 10.31 Max: 24.34
Current: 9.5
3.5
24.34
PB Ratio 2.04
TARO's PB Ratio is ranked higher than
60% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. TARO: 2.04 )
Ranked among companies with meaningful PB Ratio only.
TARO' s PB Ratio Range Over the Past 10 Years
Min: 1.18  Med: 2.61 Max: 6.4
Current: 2.04
1.18
6.4
PS Ratio 4.88
TARO's PS Ratio is ranked lower than
68% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TARO: 4.88 )
Ranked among companies with meaningful PS Ratio only.
TARO' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 3.72 Max: 9.63
Current: 4.88
1
9.63
Price-to-Free-Cash-Flow 10.63
TARO's Price-to-Free-Cash-Flow is ranked higher than
82% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. TARO: 10.63 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TARO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.93  Med: 11.15 Max: 28.21
Current: 10.63
5.93
28.21
Price-to-Operating-Cash-Flow 9.77
TARO's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. TARO: 9.77 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TARO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.68  Med: 10.53 Max: 25.85
Current: 9.77
5.68
25.85
EV-to-EBIT 7.12
TARO's EV-to-EBIT is ranked higher than
94% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. TARO: 7.12 )
Ranked among companies with meaningful EV-to-EBIT only.
TARO' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.5  Med: 7.7 Max: 52.3
Current: 7.12
4.5
52.3
EV-to-EBITDA 6.92
TARO's EV-to-EBITDA is ranked higher than
91% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. TARO: 6.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
TARO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 6.7 Max: 52.3
Current: 6.92
4
52.3
PEG Ratio 0.44
TARO's PEG Ratio is ranked higher than
97% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. TARO: 0.44 )
Ranked among companies with meaningful PEG Ratio only.
TARO' s PEG Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.3 Max: 0.49
Current: 0.44
0.22
0.49
Shiller PE Ratio 17.67
TARO's Shiller PE Ratio is ranked higher than
81% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. TARO: 17.67 )
Ranked among companies with meaningful Shiller PE Ratio only.
TARO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.6  Med: 23.56 Max: 57.88
Current: 17.67
10.6
57.88
Current Ratio 9.53
TARO's Current Ratio is ranked higher than
85% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. TARO: 9.53 )
Ranked among companies with meaningful Current Ratio only.
TARO' s Current Ratio Range Over the Past 10 Years
Min: 0.51  Med: 1.65 Max: 9.53
Current: 9.53
0.51
9.53
Quick Ratio 8.85
TARO's Quick Ratio is ranked higher than
86% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. TARO: 8.85 )
Ranked among companies with meaningful Quick Ratio only.
TARO' s Quick Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1 Max: 8.85
Current: 8.85
0.29
8.85
Days Inventory 253.61
TARO's Days Inventory is ranked lower than
90% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. TARO: 253.61 )
Ranked among companies with meaningful Days Inventory only.
TARO' s Days Inventory Range Over the Past 10 Years
Min: 163.69  Med: 211.42 Max: 278.28
Current: 253.61
163.69
278.28
Days Sales Outstanding 84.64
TARO's Days Sales Outstanding is ranked lower than
64% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. TARO: 84.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
TARO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.21  Med: 74.43 Max: 94.08
Current: 84.64
63.21
94.08
Days Payable 367.98
TARO's Days Payable is ranked higher than
97% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. TARO: 367.98 )
Ranked among companies with meaningful Days Payable only.
TARO' s Days Payable Range Over the Past 10 Years
Min: 38.15  Med: 49.29 Max: 367.98
Current: 367.98
38.15
367.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.20
TARO's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. TARO: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TARO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.4  Med: -3.2 Max: 1.5
Current: 1.2
-18.4
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.04
TARO's Price-to-Net-Cash is ranked lower than
58% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. TARO: 11.04 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TARO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.9  Med: 18.95 Max: 92.19
Current: 11.04
7.9
92.19
Price-to-Net-Current-Asset-Value 2.37
TARO's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. TARO: 2.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TARO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.37  Med: 7.4 Max: 363
Current: 2.37
2.37
363
Price-to-Tangible-Book 2.04
TARO's Price-to-Tangible-Book is ranked higher than
67% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. TARO: 2.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TARO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 2.49 Max: 21.79
Current: 2.04
0.89
21.79
Price-to-Intrinsic-Value-Projected-FCF 0.65
TARO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. TARO: 0.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TARO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.54 Max: 6.94
Current: 0.65
0.65
6.94
Price-to-Median-PS-Value 1.31
TARO's Price-to-Median-PS-Value is ranked lower than
69% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. TARO: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TARO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.48 Max: 1.89
Current: 1.31
0.1
1.89
Price-to-Peter-Lynch-Fair-Value 0.43
TARO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
95% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. TARO: 0.43 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TARO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.57 Max: 5.02
Current: 0.43
0.13
5.02
Price-to-Graham-Number 0.92
TARO's Price-to-Graham-Number is ranked higher than
83% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. TARO: 0.92 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TARO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.41  Med: 1.05 Max: 3.69
Current: 0.92
0.41
3.69
Earnings Yield (Greenblatt) % 14.04
TARO's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. TARO: 14.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TARO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 13 Max: 22.4
Current: 14.04
1.9
22.4
Forward Rate of Return (Yacktman) % 29.45
TARO's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. TARO: 29.45 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TARO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.4  Med: 3.9 Max: 53.9
Current: 29.45
-21.4
53.9

More Statistics

Revenue (TTM) (Mil) $879.4
EPS (TTM) $ 11.06
Beta0.36
Short Percentage of Float16.42%
52-Week Range $92.28 - 150.75
Shares Outstanding (Mil)41.03
» More Articles for TARO

Headlines

Articles On GuruFocus.com
Gurus' Stocks With Low P/E Ratios Oct 31 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
My Low-Debt List Has Shown a Profit 12 years out of 13 May 13 2016 
American CryoStem Corporation Retains Investor Relations Partners as Investor Relations Counsel Apr 01 2016 
These Companies Show High Profit and Low Debt Jun 17 2015 
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by Natura Mar 18 2015 
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 

More From Other Websites
Edited Transcript of TARO earnings conference call or presentation 23-May-17 12:00pm GMT May 24 2017
Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs May 23 2017
Taro posts 4Q profit May 22 2017
Taro Provides Results for Year Ended March 31, 2017 May 22 2017
Taro to Announce Results for Year Ended March 31, 2017 on May 22, 2017 May 15 2017
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US... May 15 2017
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : April 25, 2017 Apr 25 2017
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US... Apr 24 2017
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : April 5, 2017 Apr 05 2017
3 Drug Stocks With Some of the Highest Profit Margins Mar 17 2017
Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q3, 2017 By the Numbers : February... Feb 13 2017
Taro Pharma 3Q Net $140M Versus $189M Last Year Feb 10 2017
Taro Provides Results for December 31, 2016 Feb 09 2017
Taro to Announce Third Quarter Results on February 9, 2017 Jan 31 2017
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA Jan 25 2017
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : January 13, 2017 Jan 13 2017
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US... Jan 12 2017
TARO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and... Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)